Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rofecoxib reduces polyp recurrence in familial polyposis.

A Hallak1, L Alon-Baron, R Shamir

  • 1Gastrointestinal Oncology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Digestive Diseases and Sciences
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

Nature medicine·2025
Same author

Symptoms and management of cow's milk allergy: perception and evidence.

Frontiers in allergy·2024
Same author

Circadian clock gene disruption in white blood cells of patients with celiac disease.

Biochimie·2023
Same author

Pedi-R-MAPP: The development of a nutritional awareness tool for use in remote paediatric consultations using a modified Delphi consensus.

Clinical nutrition (Edinburgh, Scotland)·2022
Same author

Determinants of Pouch-Related Symptoms, a Common Outcome of Patients With Adenomatous Polyposis Undergoing Ileoanal Pouch Surgery.

Clinical and translational gastroenterology·2020
Same author

ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Guideline development process for the updated guidelines.

Clinical nutrition (Edinburgh, Scotland)·2018

Rofecoxib effectively reduced polyp formation in familial polyposis patients over 16 months. This COX-2 inhibitor was well-tolerated, showing significant polyp reduction and preventing cancer development.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Familial polyposis is an inherited condition characterized by numerous polyps in the colon.
  • These polyps have a high risk of progressing to colorectal cancer.
  • Effective long-term management strategies are crucial for preventing cancer in these patients.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of rofecoxib in managing polyps in familial polyposis patients.
  • To assess the drug's impact on polyp formation rate, size, and histological grade.
  • To determine if rofecoxib can prevent the development of cancer or high-grade adenomas.

Main Methods:

  • A prospective study involving eight familial polyposis patients treated with rofecoxib 25 mg daily.

Related Experiment Videos

  • Regular sigmoidoscopy/colonoscopy assessments every six months for polyp evaluation and removal.
  • Assessment of polyp number, size, and histological grade at baseline and throughout the follow-up period.

    • Main Results:

    • Rofecoxib demonstrated a significant reduction in polyp formation rate (70-100%) over the study period (mean follow-up of 16.4 months).
    • The mean number of polyps decreased from 15.1 at baseline to 1.6 at the end of follow-up (P = 0.008).
    • No patients developed cancer or high-grade adenomas during treatment, and the drug was well-tolerated with no significant adverse events.

    Conclusions:

    • Long-term administration of rofecoxib is a safe and effective treatment for inhibiting polyp formation in familial polyposis.
    • Rofecoxib shows promise in preventing the progression to colorectal cancer in high-risk individuals.
    • COX-2 inhibitors represent a viable therapeutic option for managing familial polyposis.